Founded in 2004, Penumbra focuses on addressing challenging medical conditions through advanced engineering and proprietary medical devices. The company's core offerings include computer-assisted vacuum thrombectomy (CAVT) systems, reperfusion catheters, and embolization devices designed to navigate complex vessels in the brain and body. Penumbra operates primarily through two main product franchises: neurovascular and peripheral vascular. The company generates revenue by selling a mix of capital equipment, such as aspiration pumps, and single-use disposable devices used during procedures. While the majority of its sales are generated in the United States, Penumbra maintains a growing international presence across more than 100 countries. In January 2026, Boston Scientific announced a definitive agreement to acquire Penumbra, a transaction expected to close later in the year.
